pHLIP

pHLIP, Inc. is a private, clinical-stage biotech leveraging its unique pH-sensitive peptide platform to enable precise targeting of acidic microenvironments found in solid tumors, inflamed, and fibrotic tissues. Its core technology allows for the selective delivery of payloads—ranging from small molecules and proteins to nanoparticles—either to the cell surface or directly into the cytoplasm, aiming to enhance efficacy and reduce systemic side effects. The company has demonstrated proof-of-concept for tumor targeting in humans and is advancing a pipeline focused on oncology and inflammatory diseases. With its platform-agnostic approach, pHLIP seeks to create novel targeted therapies and improve existing treatment modalities.

Proprietary pH-Low Insertion Peptide (pHLIP®) platform. Peptides sense low extracellular pH at cell surfaces, undergo conformational change, and insert into cell membranes to either tether payloads to the surface or translocate them into the cytoplasm of acidic diseased cells.

pHLIP competes in the targeted drug delivery space against antibody-drug conjugates (ADCs), other peptide-targeting technologies, and nanoparticle delivery systems. Its key differentiator is targeting a physiological hallmark (low pH) rather than a specific, often heterogeneous, receptor, potentially offering broader applicability across disease types.